A phase IV multicenter randomized trial tested sugammadex — a drug that reverses surgical muscle paralysis — in 138 children aged 1 to 720 days. The 2 mg/kg dose reversed moderate neuromuscular blockade nearly three times faster than the standard drug neostigmine (1.4 vs. 4.4 minutes). The 4 mg/kg dose rapidly reversed deep blockade in about 1.1 minutes. Pharmacokinetic data showed no dose adjustments were needed for younger age groups. No drug-related serious adverse events, deaths, or allergic reactions occurred. This trial provides the first robust clinical evidence supporting sugammadex use in the youngest pediatric patients, filling a critical gap in neonatal and infant anesthesia care.
